![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication March 10, 2006.
Revised October 31, 2006.
Accepted for publication November 14, 2006.
-secretase and promote the neuronal differentiation of neuroblastoma cells
-Secretase, exhibiting characteristics of aspartyl protease, mediates the intramembranous proteolysis of 
-amyloid precursor protein (APP) and Notch, and is considered to be a prime pharmacological target in the development of therapeutics for Alzheimer's disease (AD). To identify compounds that block -secretase-mediated proteolysis, we employed a highly sensitive cell-based reporter gene assay for -secretase in which Gal4/VP16-tagged C99-APP (C99-GV) was expressed as the immediate substrate of -secretase and AICD-GV released by the -secretase cleavage then activated the expression of the Gal4-driven luciferase reporter gene. Using this reporter assay, we demonstrated that the newly synthesized (hydroxyethyl)urea peptidomimetics, which contain unnatural amino acid moieties at positions P1' and/or P3', can effectively inhibit -secretase activity and significantly reduce A production. Consistently, the -secretase-dependent S3 cleavage of Notch was also blocked by these (hydroxyethyl)ureas as evidenced by the decreased generation of the Notch intracellular domain (NICD), a prerequisite for the activation of Notch signaling. The inhibition of Notch signaling by active Jia compounds efficiently promotes the neuronal differentiation of neuroblastoma cells, intervening in tumorigenesis and the malignancy of neuroblastomas. Our results suggest that (hydroxyethyl)urea peptidomimetics containing unnatural amino acid substitutions could represent a novel class of -secretase inhibitors with enhanced stability, providing the basis for the further development of effective therapeutics for AD and neuroblastomas.
Key words:
MAP Kinase, Oncogenes, Membrane targets, Neuropeptides, peptidases
This article has been cited by other articles:
|
|
 |
|
  W.-M. Hsu, H. Lee, H.-F. Juan, Y.-Y. Shih, B.-J. Wang, C.-Y. Pan, Y.-M. Jeng, H.-H. Chang, M.-Y. Lu, K.-H. Lin, et al. Identification of GRP75 as an Independent Favorable Prognostic Marker of Neuroblastoma by a Proteomics Analysis Clin. Cancer Res., October 1, 2008; 14(19): 6237 - 6245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-H. Kuo, M.-K. Hu, W.-M. Hsu, Y.-T. Tung, B.-J. Wang, W.-W. Tsai, C.-T. Yen, and Y.-F. Liao Tumor Necrosis Factor-{alpha}-elicited Stimulation of {gamma}-Secretase Is Mediated by c-Jun N-terminal Kinase-dependent Phosphorylation of Presenilin and Nicastrin Mol. Biol. Cell, October 1, 2008; 19(10): 4201 - 4212. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
